Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $3.56 down -7.29% from its previous closing price of $3.84. In other words, the price has decreased by -$7.29 from its previous closing price. On the day, 6.89 million shares were traded. AKBA stock price reached its highest trading level at $3.85 during the session, while it also had its lowest trading level at $3.5132.
Ratios:
For a deeper understanding of Akebia Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.02 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 8.39 whereas as Long-Term Debt/Eq ratio is at 7.41.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 934984128 and an Enterprise Value of 1017205568. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.06 while its Price-to-Book (P/B) ratio in mrq is 37.89. Its current Enterprise Value per Revenue stands at 5.501 whereas that against EBITDA is 99.706.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.97, which has changed by 1.5428572 over the last 52 weeks, in comparison to a change of 0.16932249 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.07. The 50-Day Moving Average of the stock is 1.63%, while the 200-Day Moving Average is calculated to be 52.35%.
Shares Statistics:
For the past three months, AKBA has traded an average of 4.75M shares per day and 3131530 over the past ten days. A total of 261.64M shares are outstanding, with a floating share count of 251.62M. Insiders hold about 4.19% of the company’s shares, while institutions hold 36.62% stake in the company. Shares short for AKBA as of 1752537600 were 25373233 with a Short Ratio of 5.34, compared to 1749772800 on 18498837. Therefore, it implies a Short% of Shares Outstanding of 25373233 and a Short% of Float of 9.7600006.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of Akebia Therapeutics Inc (AKBA) is currently in progress, with 2.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.02 and -$0.09 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is $0.26, with 2.0 analysts recommending between $0.42 and $0.11.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $47.6M this quarter.It ranges from a high estimate of $50.8M to a low estimate of $45.6M. As of the current estimate, Akebia Therapeutics Inc’s year-ago sales were $43.65MFor the next quarter, 5 analysts are estimating revenue of $46.64M. There is a high estimate of $48.89M for the next quarter, whereas the lowest estimate is $44M.
A total of 5 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $206.14M, while the lowest revenue estimate was $192.8M, resulting in an average revenue estimate of $200.93M. In the same quarter a year ago, actual revenue was $160.18MBased on 5 analysts’ estimates, the company’s revenue will be $289.1M in the next fiscal year. The high estimate is $395.54M and the low estimate is $216.9M.
